Ben Woolven
Consultant / Advisor en Resolution Therapeutics Ltd. .
Perfil
Ben joined Syncona from GlaxoSmithKline where he has over a decade of strategy development, business operations and project management experience.
Latterly Ben worked with GlaxoSmithKline’s Chief Medical Officer, where he led reconfiguration of global and regional medical functions in anticipation of their evolving pharma portfolio.
Prior to this, Ben held various strategy and operations roles building scientific teams, developing justifications for new scientific investments, leading project management offices and providing R&D consultancy support, including a secondment to L.E.K Consulting.
Prior to joining GlaxoSmithKline Ben played a key role in the success of Domantis, an antibody fragment start-up, sold to GlaxoSmithKline for £230 million.
Ben holds a PhD in Immunology.
Cargos activos de Ben Woolven
Empresas | Cargo | Inicio |
---|---|---|
Resolution Therapeutics Ltd.
Resolution Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Resolution Therapeutics Ltd. operates as a macrophage cell therapy company. The company was founded on December 14, 2017 and is headquartered in London, the United Kingdom. | Consultant / Advisor | 01/02/2022 |
Antiguos cargos conocidos de Ben Woolven.
Empresas | Cargo | Fin |
---|---|---|
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Private Equity Investor | 01/11/2022 |
GSK PLC | Director/Board Member | 01/02/2022 |
Domantis Ltd.
Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | Corporate Officer/Principal | 01/02/2009 |
Formación de Ben Woolven.
University of Cambridge | Undergraduate Degree |
University of Kent | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
GSK PLC | Health Technology |
Empresas privadas | 3 |
---|---|
Domantis Ltd.
Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | Health Technology |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Finance |
Resolution Therapeutics Ltd.
Resolution Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Resolution Therapeutics Ltd. operates as a macrophage cell therapy company. The company was founded on December 14, 2017 and is headquartered in London, the United Kingdom. | Commercial Services |
- Bolsa de valores
- Insiders
- Ben Woolven